Molecular Determinants of Invasion in Endometrial Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2007 May 26

PMID 17525037

Citations 18

Authors

M Abal

M Llaurado

A Doll

M Monge

E Colas

M Gonzalez

M Rigau

H Alazzouzi

S Demajo

J Castellvi

A Garcia

S Ramon Y Cajal

J Xercavins

M H Vazquez-Levin

F Alameda

A Gil-Moreno

J Reventos

Affiliations

Soon will be listed here.

Abstract

Endometrial carcinoma is the most common gynaecological malignancy in the western world and the most frequent among infiltrating tumours of the female genital tract. Despite the characterisation of molecular events associated with the development of endometrial carcinoma, those associated with the early steps of infiltration and invasion in endometrial cancer are less known. Deep myometrial invasion correlates with more undifferentiated tumours, lymph-vascular invasion, node affectation and decreased global survival. In this review we present an overview of the molecular pathology of myometrial infiltration that defines the initial steps of invasion in endometrial cancer. Down-regulation of E-cadherin as a main player of epithelial to mesenchymal transition, as well as modifications on other molecules involved in cell-cell contacts, render cells with a migratory phenotype. In addition, altered signalling pathways and transcription factors associate with myometrial invasion, histologic grade and metastasis.

Citing Articles

Expression of E-Cadherin and N-Cadherin in the Endocervix as a Predictive Factor in Patients with Endometrial Cancer.

Fraszczak K, Barczynski B, Tylus B, Bednarek W Int J Mol Sci. 2024; 25(6).

PMID: 38542521 PMC: 10970815. DOI: 10.3390/ijms25063547.

Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness.

Sonzini G, Granados-Aparici S, Sanegre S, Diaz-Lagares A, Diaz-Martin J, de Andrea C Front Cell Dev Biol. 2022; 10:1052098.

PMID: 36467415 PMC: 9716026. DOI: 10.3389/fcell.2022.1052098.

Proteomic and functional characterization of intra-tumor heterogeneity in human endometrial cancer.

Jamaluddin M, Ko Y, Ghosh A, Syed S, Ius Y, OSullivan R Cell Rep Med. 2022; 3(9):100738.

PMID: 36103879 PMC: 9512672. DOI: 10.1016/j.xcrm.2022.100738.

Endometrial Tumour Microenvironment.

Casas-Arozamena C, Abal M Adv Exp Med Biol. 2021; 1296:215-225.

PMID: 34185295 DOI: 10.1007/978-3-030-59038-3_13.

Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma.

Sanegre S, Eritja N, de Andrea C, Diaz-Martin J, Diaz-Lagares A, Jacome M Front Cell Dev Biol. 2021; 9:670185.

PMID: 34150764 PMC: 8209546. DOI: 10.3389/fcell.2021.670185.

References

Noe V, Willems J, Vandekerckhove J, Roy F, Bruyneel E, Mareel M . Inhibition of adhesion and induction of epithelial cell invasion by HAV-containing E-cadherin-specific peptides. J Cell Sci. 1998; 112 ( Pt 1):127-35. DOI: 10.1242/jcs.112.1.127. View

Dai D, Wolf D, Litman E, White M, Leslie K . Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 2002; 62(3):881-6. View

Nei H, Saito T, Yamasaki H, Mizumoto H, Ito E, Kudo R . Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Mol Carcinog. 1999; 25(3):207-18. View

Kobayashi K, Sagae S, Nishioka Y, Tokino T, Kudo R . Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res. 1999; 90(1):55-9. PMC: 5925974. DOI: 10.1111/j.1349-7006.1999.tb00665.x. View

Nishimura M, Saito T, Yamasaki H, Kudo R . Suppression of gap junctional intercellular communication via 5' CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells. Carcinogenesis. 2003; 24(10):1615-23. DOI: 10.1093/carcin/bgg121. View

Larue L, Bellacosa A . Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005; 24(50):7443-54. DOI: 10.1038/sj.onc.1209091. View

Palacios J, Catasus L, Moreno-Bueno G, Matias-Guiu X, Prat J, Gamallo C . Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Arch. 2001; 438(5):464-9. DOI: 10.1007/s004280000371. View

Sakaguchi J, Kyo S, Kanaya T, Maida Y, Hashimoto M, Nakamura M . Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer. Gynecol Oncol. 2005; 98(3):427-33. DOI: 10.1016/j.ygyno.2005.04.031. View

Moreno-Bueno G, Hardisson D, Sarrio D, Sanchez C, Cassia R, Prat J . Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol. 2003; 199(4):471-8. DOI: 10.1002/path.1310. View

10.

Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J . E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol. 2002; 100(6):1290-5. DOI: 10.1016/s0029-7844(02)02391-8. View

11.

Ohtani K, Sakamoto H, Rutherford T, Chen Z, Satoh K, Naftolin F . Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells. Cancer Lett. 2000; 147(1-2):31-8. DOI: 10.1016/s0304-3835(99)00272-4. View

12.

Yoshida H, Broaddus R, Cheng W, Xie S, Naora H . Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial-mesenchymal transition. Cancer Res. 2006; 66(2):889-97. DOI: 10.1158/0008-5472.CAN-05-2828. View

13.

Shih H, Shiozawa T, Miyamoto T, Kashima H, Feng Y, Kurai M . Immunohistochemical expression of E-cadherin and beta-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression. Anticancer Res. 2005; 24(6):3843-50. View

14.

Mutter G, Lin M, Fitzgerald J, Kum J, Baak J, Lees J . Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000; 92(11):924-30. DOI: 10.1093/jnci/92.11.924. View

15.

Chambers A, Groom A, MacDonald I . Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2(8):563-72. DOI: 10.1038/nrc865. View

16.

Uegaki K, Kanamori Y, Kigawa J, Kawaguchi W, Kaneko R, Naniwa J . PTEN is involved in the signal transduction pathway of contact inhibition in endometrial cells. Cell Tissue Res. 2005; 323(3):523-8. DOI: 10.1007/s00441-005-0082-3. View

17.

Thiery J, Morgan M . Breast cancer progression with a Twist. Nat Med. 2004; 10(8):777-8. DOI: 10.1038/nm0804-777. View

18.

Kang Y, Massague J . Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004; 118(3):277-9. DOI: 10.1016/j.cell.2004.07.011. View

19.

Dai D, Litman E, Schonteich E, Leslie K . Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Mol Biol. 2003; 87(2-3):123-31. DOI: 10.1016/j.jsbmb.2003.08.004. View

20.

Salvesen H, Stefansson I, Kretzschmar E, Gruber P, MacDonald N, Ryan A . Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol. 2004; 25(6):1615-23. View